Two Sigma Securities LLC Takes $965,000 Position in Guardant Health, Inc. $GH

Two Sigma Securities LLC bought a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 6,432 shares of the company’s stock, valued at approximately $965,000.

A number of other large investors also recently added to or reduced their stakes in GH. Orbimed Advisors LLC purchased a new stake in Guardant Health during the first quarter valued at about $40,199,000. World Investment Advisors purchased a new position in shares of Guardant Health in the fourth quarter worth about $1,664,000. GSA Capital Partners LLP purchased a new position in shares of Guardant Health in the second quarter worth about $1,772,000. Ninepoint Partners LP bought a new stake in shares of Guardant Health in the 2nd quarter valued at about $2,853,000. Finally, Eagle Health Investments LP bought a new stake in shares of Guardant Health in the 2nd quarter valued at about $45,112,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. BTIG Research raised their price target on Guardant Health from $190.00 to $195.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Evercore reissued an “outperform” rating and set a $200.00 price objective on shares of Guardant Health in a research note on Monday, July 6th. Barclays raised their target price on shares of Guardant Health from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Bank of America upped their price target on shares of Guardant Health from $135.00 to $190.00 and gave the company a “buy” rating in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $183.78.

Insider Activity at Guardant Health

In related news, CEO Amirali Talasaz sold 143,028 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $151.54, for a total value of $21,674,463.12. Following the completion of the transaction, the chief executive officer directly owned 1,881,336 shares of the company’s stock, valued at $285,097,657.44. This represents a 7.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the sale, the chief executive officer owned 2,012,919 shares of the company’s stock, valued at $254,231,669.70. This trade represents a 4.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 548,318 shares of company stock valued at $82,501,873 over the last three months. Corporate insiders own 5.60% of the company’s stock.

Guardant Health Price Performance

GH opened at $159.02 on Tuesday. Guardant Health, Inc. has a one year low of $53.40 and a one year high of $176.58. The business has a 50 day simple moving average of $158.10 and a two-hundred day simple moving average of $121.24. The firm has a market capitalization of $21.34 billion, a price-to-earnings ratio of -45.56 and a beta of 1.60.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to the consensus estimate of $314.23 million. During the same quarter in the prior year, the business posted ($0.44) earnings per share. Guardant Health’s quarterly revenue was up 44.3% compared to the same quarter last year. As a group, sell-side analysts expect that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.